RESEARCHDIAGNOSTICSTRANSLATIONOUTREACH
 
Helena Pópulo
Name: Helena Pópulo
E-mail: hpopulo@ipatimup.pt
Extension: 
225570700
Academic Degree: PhD


Helena Pópulo
Helena Pópulo
Member of
Assistant Researcher of Cancer Signalling & Metabolism


Short CV

Highlights

Supervisor of
Beatriz Correia, Master Student (theoretical phase)
MSc student

PI (running)

PI (closed)
Development of a biomimetic multifunctional pré-clinical model to assist immunotherapy optimization.
First Author
 
C
IF
1. Pópulo H, Domingues B, Sampaio C, Lopes JM, Soares P
Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. Journal of experimental pharmacology 13: 521-535, 2021. [Article] 
 doi: 10.2147/JEP.S297831 PMID: 34079392.
 
0
-
2. Pópulo H, Nunes B, Sampaio C, Batista R, Pinto MT, Gaspar TB, Miranda-Alves L, Cai RZ, Zhang XY, Schally AV, Sobrinho-Simões M, Soares P
Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. Hormones & cancer 8: 314-324, 2017. [Article] 
 doi: 10.1007/s12672-017-0307-4 PMID: 28924876.
 
10
2.6
3. Pópulo H, Batista R, Sampaio C, Pardal J, Lopes JM, Soares P
SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. PloS one 12: e0180392, 2017. [Article] 
 doi: 10.1371/journal.pone.0180392 PMID: 28662141.
 
2
2.8
4. Pópulo H, Caldas R, Lopes JM, Pardal J, Máximo V, Soares P
Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. Expert opinion on therapeutic targets 19: 733-45, 2015. [Article] 
 doi: 10.1517/14728222.2015.1045416 PMID: 25976231.
 
22
4.8
5. Pópulo H, Lopes JM, Sobrinho-Simões M, Soares P
RE: TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. Journal of the National Cancer Institute 107: 1, 2015. [Letter] 
 doi: 10.1093/jnci/djv049 PMID: 25755155.
 
3
11.4
6. Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, Pardal J, Azevedo F, Honavar M, Guimarães I, Manuel Lopes J, Sobrinho-Simões M, Soares P
TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation. The Journal of investigative dermatology 134: 2251-7, 2014. [Article] 
 doi: 10.1038/jid.2014.163 PMID: 24691053.
 
95
7.2
7. Pópulo H, Tavares S, Faustino A, Nunes JB, Lopes JM, Soares P
GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. PeerJ 1: e104, 2013. [Article] 
 doi: 10.7717/peerj.104 PMID: 23904987.
 
9
-
8. Pópulo H, Lopes JM, Soares P
The mTOR Signalling Pathway in Human Cancer. International journal of molecular sciences 13: 1886-918, 2012. [Review] 
 doi: 10.3390/ijms13021886 PMID: 22408430.
 
583
2.5
9. Pópulo H, Soares P, Lopes JM
Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert opinion on therapeutic targets 16: 689-705, 2012. [Review] 
 doi: 10.1517/14728222.2012.691472 PMID: 22620498.
 
32
4.1
10. Pópulo H, Soares P, Faustino A, Rocha AS, Silva P, Azevedo F, Lopes JM
mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment cell & melanoma research 24: 254-7, 2011. [Letter] 
 doi: 10.1111/j.1755-148X.2010.00796.x PMID: 21029395.
 
31
5.1
11. Pópulo H, Vinagre J, Lopes JM, Soares P
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. The British journal of ophthalmology 95: 715-9, 2011. [Article] 
 doi: 10.1136/bjo.2009.174417 PMID: 20805136.
 
31
2.9
12. Pópulo H, Soares P, Rocha AS, Silva P, Lopes JM
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma research 20: 107-17, 2010. [Article] 
 doi: 10.1097/CMR.0b013e32832ccd09 PMID: 20173664.
 
62
2.3
Senior Author
 
C
IF
1. Martins F, Martins C, Fernandes MS, Andrade MI, Lopes JM, Soares P, Pópulo H
TERT Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy. Dermatology (Basel, Switzerland)  , 2021. [Article - 1-10; Epub ahead of print] 
 doi: 10.1159/000518219 PMID: 34569488.
 
0
5.4 (*)
2. Sampaio C, Domingues B, Soares P, Lopes JM, Populo H
Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment European journal of cancer (Oxford, England : 1990) 138: S23-S23, 2020. [Meeting Abstract] 
.
 
0
7.3 (*)
3. Domingues B, Lopes JM, Soares P, Pópulo H
Melanoma treatment in review. ImmunoTargets and therapy 7: 35-49, 2018. [Review] 
 doi: 10.2147/ITT.S134842 PMID: 29922629.
 
336
-
@ 2014 Ipatimup Institute of Molecular Pathology and Immunology of the University of Porto
A
A
A

Send Email
From
To
Subject